(2)
-Announced new positive data in human experimental model of inflammation of EDP1815-
-Completed enrollment in Phase 2b dose-ranging trial for EDP1815 in psoriasis; full data set accelerated and now expected in 3Q 2021-
-Initiated Phase 1b clinical trial of EDP1867 in atopic dermatitis; data expected in 4Q 2021-
-Up to 8 clinical data readouts expected over next 18 months-
-Management to host conference call at 8:30 a.m. ET-
CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today reported financial results and business highlights for the fourth quarter and full year 2020.
Genomic Medicine Stands on the Shoulders of Giants
Source: Boris SV/Getty Images
Genomic Medicine Stands on the Shoulders of Giants
With the benefit of rich, diverse data stores and computational power, scientists in precision medicine are finally realizing ambitions inspired long ago by the Human Genome Project
Share
When the first published drafts of the human genome appeared 20 years ago, scientists proclaimed that an outpouring of genomically informed medical advances was imminent. For example, Francis S. Collins, MD, PhD, then director of the National Human Genome Research Institute, and Victor A. McKusick, MD, professor of medical genetics at Johns Hopkins University, predicted that by 2020, the impact of genetics on medicine would be “widespread.” They shared more detailed expectations in a paper titled, “Implications of the Human Genome Project for Medical Science” (
Milwaukee, WI (PRWEB) March 04, 2021 The Society for Immunotherapy of Cancer (SITC) is pleased to announce the return of a successful initiative focused on
Zai Lab Announces Financial Results for Second-half and Full-year 2020
March 01, 2021 07:00 ET | Source: Zai Lab Limited Zai Lab Limited Company to Host Conference Call and Webcast Today at 8:00 a.m. ET
SHANGHAI and SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today reported financial results for the second half and full year of 2020, along with corporate updates.
“2020 was another year of great accomplishment for Zai Lab,” said Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab. “We successfully launched ZEJULA for both second-line and first-line ovarian cancer and Optune for glioblastoma in China. We submitted NDAs and were granted priority reviews by China’s National Medical Products Administration (NMPA) for both QINLOCK for advanced gastrointestinal stromal tumors (GIST) and NUZYRA for community-acquire
Introduction
Pleading requirements in federal courts, particularly in securities class action cases, have become increasingly difficult, if not impossible, to satisfy. On December 30, 2020, a U.S. district court in California granted the motion of the biopharmaceutical company, Nektar Therapeutics, Inc. (“Nektar” or “Company”)
1 and its named officers (collectively, “Defendants”) to dismiss Plaintiffs’ second-amended securities fraud complaint (“Complaint”) by means of an opinion that stretched, we believe, well beyond the applicable pleading rules and statutes. Being the second dismissal in the case, the court denied Plaintiffs representatives of a putative class of shareholders of Nektar stock a third chance to amend their Complaint.